| GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPAR … JM Seargent, EA Yates, JH Gill British journal of pharmacology 143 (8), 933-937, 2004 | 239 | 2004 |
| Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle AN Mardaryev, MI Ahmed, NV Vlahov, MY Fessing, JH Gill, AA Sharov, ... The FASEB Journal 24 (10), 3869, 2010 | 193 | 2010 |
| Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas I Fichtner, W Slisow, J Gill, M Becker, B Elbe, T Hillebrand, M Bibby European journal of cancer 40 (2), 298-307, 2004 | 183 | 2004 |
| Development of novel tumor‐targeted theranostic nanoparticles activated by membrane‐type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy C Ansari, GA Tikhomirov, SH Hong, RA Falconer, PM Loadman, JH Gill, ... Small 10 (3), 566-575, 2014 | 165 | 2014 |
| Phospholipase A2 expression in tumours: a target for therapeutic intervention? JP Laye, JH Gill Drug discovery today 8 (15), 710-716, 2003 | 157 | 2003 |
| Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development P Gibson, JH Gill, PA Khan, JM Seargent, SW Martin, PA Batman, J Griffith, ... Molecular cancer therapeutics 2 (6), 527-534, 2003 | 150 | 2003 |
| Drug discovery and evaluation: safety and pharmacokinetic assays; with 125 tables HG Vogel, J Maas Springer Science & Business Media, 2006 | 148 | 2006 |
| Non‐invasive molecular imaging for preclinical cancer therapeutic development AC O'farrell, SD Shnyder, G Marston, PL Coletta, JH Gill British journal of pharmacology 169 (4), 719-735, 2013 | 130 | 2013 |
| Non-genotoxic hepatocarcinogenesis stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations RA Roberts, AR Soames, JH Gill, NH James, EB Wheeldon Carcinogenesis 16 (8), 1693-1698, 1995 | 130 | 1995 |
| Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity A Krippner-Heidenreich, I Grunwald, G Zimmermann, M Kühnle, ... The Journal of Immunology 180 (12), 8176-8183, 2008 | 111 | 2008 |
| Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids SS Jensen, TL Andresen, J Davidsen, P Høyrup, SD Shnyder, MC Bibby, ... Molecular cancer therapeutics 3 (11), 1451-1458, 2004 | 110 | 2004 |
| MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas JH Gill, IG Kirwan, JM Seargent, SW Martin, S Tijani, VA Anikin, ... Neoplasia 6 (6), 777-785, 2004 | 101 | 2004 |
| Negative regulation of G1/S transition by the candidate bladder tumour suppressor gene DBCCR1 H Nishiyama, JH Gill, E Pitt, W Kennedy, MA Knowles Oncogene 20 (23), 2956-2964, 2001 | 81 | 2001 |
| Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases JM Atkinson, RA Falconer, DR Edwards, CJ Pennington, CS Siller, ... Cancer research 70 (17), 6902-6912, 2010 | 79 | 2010 |
| Tumour endoproteases: the cutting edge of cancer drug delivery? JM Atkinson, CS Siller, JH Gill British journal of pharmacology 153 (7), 1344-1352, 2008 | 71 | 2008 |
| Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression … JM Atkinson, CJ Pennington, SW Martin, VA Anikin, AJ Mearns, ... European journal of cancer 43 (11), 1764-1771, 2007 | 67 | 2007 |
| Loss of tumourigenicity of stably ERβ-transfected MCF-7 breast cancer cells D Behrens, JH Gill, I Fichtner Molecular and cellular endocrinology 274 (1-2), 19-29, 2007 | 62 | 2007 |
| Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics JH Gill, KL Rockley, C De Santis, AK Mohamed Pharmacology & therapeutics 202, 18-31, 2019 | 56 | 2019 |
| Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder M Sutherland, JH Gill, PM Loadman, JP Laye, HM Sheldrake, ... Molecular cancer therapeutics 12 (1), 27-37, 2013 | 54 | 2013 |
| Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192 M Boissinot, M Inman, A Hempshall, SR James, JH Gill, P Selby, ... Leukemia research 36 (10), 1304-1310, 2012 | 54 | 2012 |
Paul LoadmanProfessor of Pharmacokinetics and Drug Metabolism, University of BradfordVerified email at Bradford.ac.uk
